Publications by authors named "Eva Sum"

Claim this Profile
T
The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation.
Eva Sum, Moritz Rapp, Harald Dürr, Alekhya Mazumdar, Pedro J Romero

J Immunother Cancer· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity.
Eva Sum, Moritz Rapp, Philipp Fröbel, Marine Le Clech, Harald Dürr

Clin Cancer Res· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD40 Agonist Targeted to Fibroblast Activation Protein α Synergizes with Radiotherapy in Murine HPV-Positive Head and Neck Tumors.
Sara Labiano, Vincent Roh, Céline Godfroid, Agnès Hiou-Feige, Jackeline Romero, Eva Sum

Clin Cancer Res· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy.
Maud Mayoux, Andreas Roller, Vesna Pulko, Stefano Sammicheli, Stanford Chen, Eva Sum

Sci Transl Med· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tonic and phasic pyloric activity in response to CCK-octapeptide.
Frank K Friedenberg, Joshua Desipio, Annapurna Korimilli, Matthew Bohning, Eva Sum

Dig Dis Sci· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis